Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.75 |
| ▸ | ALPL | P05186 | 5/20 | 0.75 |
| ▸ | RAB9A | P51151 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.69 |
| ▸ | RET | P07949 | 1/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.69 |
| ▸ | PIM1 | P11309 | 1/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.69 |
| ▸ | GSK3B | P49841 | 1/20 | 0.69 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.69 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.69 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.69 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1314014 | 0.98 | GAA (0.97) | GAAMAPTALPLRAB9APOLB | |
| SCHEMBL2839015 | 0.87 | GAA (0.77) | GAAMAPTALPLRAB9APOLB | |
| SCHEMBL4788746 | 0.86 | GAA (0.75) | GAAMAPTALPLRAB9APOLB | |
| SCHEMBL1414008 | 0.84 | MAPT (1.00) | GAAMAPTALPLRAB9APOLB | |
| SCHEMBL2524441 | 0.84 | ALPL (0.76) | GAAMAPTALPLRAB9APOLB | |
| SCHEMBL2631731 | 0.84 | MAPT (1.00) | GAAMAPTALPLRAB9APOLB | |
| SCHEMBL855912 | 0.84 | ALPL (0.76) | GAAMAPTALPLRAB9APOLB | |
| SCHEMBL644698 | 0.84 | GAA (0.72) | GAAMAPTALPLRAB9APOLB | |
| SCHEMBL13539290 | 0.84 | ALPL (1.00) | GAAMAPTALPLRAB9APOLB | |
| SCHEMBL644902 | 0.84 | MAPT (0.72) | GAAMAPTALPLRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164329-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | The Burnham Institute for Medical Research (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-06-18 | — | — | US | claimed |
| WO-2009017863-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-05 | — | — | WO | claimed |
| US-20230119740-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2023287793-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20220105091-A1 | FUSED TRICYCLIC PYRAZOLO-DIHYDROPYRAZINYL-PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2022-04-07 | — | — | US | disclosed |
| US-11234977-B2 | Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals | NOVARTIS AG (CH) | 2022-02-01 | — | — | US | disclosed |
| US-11234977-B2 | Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals | NOVARTIS AG (CH) | 2022-02-01 | — | — | US | disclosed |
| CN-108834415-B | Substituted tricyclic 1, 4-benzodiazepine derivatives as allosteric modulators of group II metabotropic glutamate receptors | 多曼治疗学公司 | 2021-12-24 | — | — | CN | disclosed |
| US-20210346377-A1 | Fused Tricyclic Pyrazolo-Dihydropyrazinyl-Pyridone Compounds as Antivirals | NOVARTIS AG (CH) | 2021-11-11 | — | — | US | disclosed |
| US-20210346377-A1 | Fused Tricyclic Pyrazolo-Dihydropyrazinyl-Pyridone Compounds as Antivirals | NOVARTIS AG (CH) | 2021-11-11 | — | — | US | disclosed |
| WO-2009017863-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1797072-A2 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006033943-A2 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-0784612-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1997001551-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-16 | — | — | WO | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346377-A1 | Fused Tricyclic Pyrazolo-Dihydropyrazinyl-Pyridone Compounds as Antivirals | ZC3HAV1, CYP3A5, HAVCR2 | GAA 1688/4885MAPT 2337/4885ALPL 1261/4885 |
| US-20230119740-A1 | THERAPEUTIC COMPOUNDS AND METHODS | PCK1, SLC5A1, PFKFB1 | GAA 818/4885MAPT 3652/4885ALPL 1024/4885 |
| US-20220105091-A1 | FUSED TRICYCLIC PYRAZOLO-DIHYDROPYRAZINYL-PYRIDONE COMPOUNDS AS ANTIVIRALS | ZC3HAV1, CYP3A5, HAVCR2 | GAA 1688/4885MAPT 2337/4885ALPL 1261/4885 |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | GAA 40/4885MAPT 3950/4885ALPL 1/4885 |
| US-11234977-B2 | Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals | ZC3HAV1, CYP3A5, HAVCR2 | GAA 1688/4885MAPT 2337/4885ALPL 1261/4885 |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | MAP3K1, MAP3K3, MAP3K5 | GAA 2413/4885MAPT 3472/4885ALPL 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.